COMPASS Pathways announces changes to its leadership team

M Matthew Owen s appointed General Counsel and Legal council ;

Lars Wilde, Chief Business Officer and co-founder, settles Senior to advise orie role

London, United Kingdom December 16, 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation by mental health matters, today announced the appointment of Matthew Owens as General Counsel and Chief Legal Officer. Mr. Owens will join COMPASS on February 1, 2022. The company also announced that Lars Wilde, President, Chief Commercial Officer and Co-Founder, will take up a senior advisor role at COMPASS effective January 1, 2022.

Matthew Owens joins COMPASS from Novartis International, where he is Global Head Legal, Digital, in charge of the development and execution of legal and IP strategy. He has been with Novartis since 2010, also serving as Senior Legal Counsel and Head Legal, Strategic Partnerships and Digital. Named “Most Innovative European In-House Lawyer 2015” by the Financial Times, Mr. Owens has extensive experience leading legal teams in the areas of digital transformation, biotechnology and innovation. Prior to Novartis, he was Senior Counsel at Solvay Pharmaceuticals and Corporate Counsel at Mettler-Toledo. He holds a Bachelor of Arts (Pre-Law and Political Science, History and Criminology) from Capital University, Columbus, Ohio, and a JD (Doctor of Laws) from Capital University Law School where he was presidential scholar. He is a lecturer at the Europa Institute of the Faculty of Law of the University of Zurich.

Matthew Owens said, “COMPASS brings innovation to mental health care, and I’m excited to join them. I am passionate about digital health and improving the patient experience and look forward to working with the COMPASS team as they continue to develop new therapies supported by digital technologies.

Lars Wilde joined COMPASS in 2017 as a co-founder and has been instrumental in the company’s many accomplishments in a number of strategic and operational areas including fundraising, business development and business development. its discovery center.

Lars Wilde said, “We have built an amazing business at COMPASS and I am grateful to everyone who continues to support us. We are the clear leader in the development of psilocybin therapy for unmet mental health needs, initially in treatment-resistant depression, and now moving into PTSD and other illnesses. We are building a portfolio of new psychedelic compounds through our Discovery Center and our partnerships. We have raised over $ 429 million and have built a strong team of over 120 talented, passionate and dedicated people. Above all, we have maintained our commitment to patients and to our goal of transforming mental health care. This is the natural time for me to move into an advisory role and I am proud to be able to continue working with COMPASS. ”

George Goldsmith, CEO and Co-Founder of COMPASS Pathways, said: “COMPASS has grown rapidly since its inception in 2016. Our mission and commitment to patients remains the same, but operationally we are a business. very different and our leadership team is evolving to reflect that. Earlier this month, we announced the appointment of Mike Falvey as the new CFO, with experience in launching and commercializing innovation for patients. As General Counsel, Matt will bring significant expertise in technology, digital health and innovation. We are delighted to welcome him to our team and are excited to work together to transform mental health care. ”

George Goldsmith continued, “The three COMPASS co-founders have always worked closely and tirelessly to create a new kind of business to transform mental health care. Without Lars COMPASS wouldn’t be where it is today. He helped us transform from the start. – to a well-funded Nasdaq listed company with the best team, a strong pipeline and a real opportunity to make a difference for patients. We will miss being here every day, but we look forward to his continued contributions as a senior advisor and support as a major shareholder. We are excited to see what Lars does next as we are sure it will be a success! ”

-Ends-

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our goal is to improve the lives of those with mental health problems who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a breakthrough therapy by the United States Food and Drug Administration (FDA) for treatment-resistant depression (TRD), and we have completed a Phase IIb clinical trial of psilocybin therapy for TRD, at 22 sites in Europe and North America. . This was the largest randomized, controlled, double-blind clinical trial of psilocybin therapy ever to be conducted, and our baseline data showed a statistically significant effect (p www.compasspathways.com

Availability of other information on COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com) and on social media (LinkedIn ), including, but not limited to, investor presentations and investor information sheets, documents filed with the United States Securities and Exchange Commission, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be considered important information. Therefore, we encourage investors, the media and others interested in us to regularly review the information posted on these channels, including the Investor Relations website. This channel list may be updated from time to time on our Investor Relations website and may include additional social media channels. The content of our website or these channels, or any other website accessible from our website or these channels, will not be deemed to be incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements may be identified by words such as “could”, “could”, “will”, “could”, “should”, “should”, “expect”, “intention”. “,” Plan “,” goal “,” anticipate “,” believe “,” contemplate “,” estimate “,” predict “,” potential “,” continue “and” in progress “or the negative of these terms or d ‘other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding, among other things, the effectiveness of COMP360 psilocybin therapy for the treatment of depression, the business strategy and objectives of COMPASS, including its ability to launch and market products. , COMPASS’s ability to continue to advance its research or develop plans to bring its products to patients, including COMP360, and COMPASS’s expectations regarding the benefits of its psilocybin therapy and the effectiveness of its leadership team . The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on such forward-looking statements as they involve known and unknown risks, uncertainties and other factors, many of which are outside the control of COMPASS and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.

These risks, uncertainties and other factors include, among others: and the risks and uncertainties described under the heading “Risk Factors” in the COMPASS Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) of United States on March 9, 2021 and in subsequent COMPASS filings with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility to update or revise any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

Surveys

Media: Tracy Cheung, [email protected], +44 7966 309024
Investors: Stephen Schultz, [email protected], +1 401 290 7324

Main logo


Source link

Comments are closed.